W.R. Berkley Corp’s Revelation Biosciences REVB Stock Holding History

W.R. Berkley Corp’s Portfolio REVB Stock Details REVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2	Closed	-$3.3M	–	578
2021 Q4	$3.3M	Buy	2 +1	+100%	+$2.04M	0.18%	125
2021 Q3	$3.03M	Hold	1	–	–	0.2%	103
2021 Q2	$1.53M	Hold	1	–	–	0.15%	127
2021 Q1	$1.23M	Hold	1	–	–	0.14%	102
2020 Q4	$1.02M	Buy	+1	New	+$2.02M	0.17%	99

Other funds holding REVB

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

MFA

Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

W.R. Berkley Corp's REVB Position: Q1 2022 in Review

W.R. Berkley Corp sold out of Revelation Biosciences (REVB) in Q1 2022, closing a stake of 2 shares — an estimated $3.3M sold.

W.R. Berkley Corp first reported a position in REVB in Q4 2020 and held it in 5 quarters. The position peaked at $3.3M in Q4 2021. 2 funds tracked by Wall St. Rank hold REVB as of Q1 2022.

W.R. Berkley Corp reported no remaining Revelation Biosciences position as of Q1 2022 after selling out during the quarter.
W.R. Berkley Corp sold 2 Revelation Biosciences shares in Q1 2022, an estimated $3.3M.
W.R. Berkley Corp first reported a position in Revelation Biosciences in Q4 2020 and held it in 5 quarters.
W.R. Berkley Corp's Revelation Biosciences position peaked at $3.3M in Q4 2021.
2 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2022.

Based on W.R. Berkley Corp's 13F filing for Q1 2022, filed 16 May 2022.